Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $7.5
BTIG Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $5
Akebia Therapeutics Analyst Ratings
Akebia Therapeutics Analyst Ratings
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $7.5
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $7.5
Buy Rating Reaffirmed for Akebia Therapeutics Ahead of Vafseo's Market Launch
Akebia Therapeutics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: GeoVax Labs (GOVX), Akebia Therapeutics (AKBA) and Aveanna Healthcare Holdings (AVAH)
Buy Rating Justified by Akebia Therapeutics' Strengthened Dialysis Negotiations and Positive Commercial Prospects
Piper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)
Akebia Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Akebia Therapeutics (AKBA) and Moderna (MRNA)
Analysts' Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)
Akebia Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $5 Price Target
BTIG Assumes Akebia Therapeutics at Buy, Announces Price Target of $4
Akebia Therapeutics Analyst Ratings
Akebia Therapeutics Analyst Ratings